Destiny Pharma PLC teams up with US Department of Veterans Affairs to find ‘new attributes’ for its next-generation antibiotic
NTCD-M3 is staying produced to fight Clostridioides difficile infections (CDI) in the intestine () mentioned it is teaming up with...